AIMS: Toll-like receptor (TLR)-mediated signalling pathways have been implicated in myocardial ischaemia/reperfusion (I/R) injury. Activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway protects the myocardium from ischaemic injury. We hypothesized that the modulation of TLR2 would induce cardioprotection against I/R injury via activation of the PI3K/Akt signalling. METHODS AND RESULTS: Mice were treated with TLR2 ligands, peptidoglycan (PGN) or Pam3CSK4, respectively, 1 h before the hearts were subjected to ischaemia (1 h), followed by reperfusion (4 h). Infarct size was determined by triphenyltetrazolium chloride staining. Cardiac function and haemodynamic performance were evaluated. Infarct size was significantly reduced in PGN- or Pam3CSK4-treated mice compared with untreated I/R mice. Administration of TLR2 ligands improved cardiac function following I/R. PGN treatment increased the levels of phospho-Akt and phospho-GSK-3beta (glycogen synthase kinase-3beta), compared with untreated I/R hearts. PGN stimulation increased TLR2 tyrosine phosphorylation and association of the p85 subunit of PI3K with TLR2. To investigate the role of PI3K/Akt signalling in PGN-induced cardioprotection, we administered the PI3K inhibitor, Wortmannin, to the mice 15 min before PGN treatment. We also administered PGN to kinase-deficient Akt (kdAkt) transgenic mice 1 h before myocardial I/R. Both PI3K inhibition and kdAkt mice abolished the cardioprotection induced by PGN. To examine the role of TLR2 in PGN-induced cardioprotection, we administrated PGN to TLR2 knockout mice 1 h before the hearts were subjected to I/R. PGN-induced cardioprotection was lost in TLR2-deficient mice. CONCLUSION: These results demonstrate that TLR2 ligands induced cardioprotection, which is mediated through a TLR2/PI3K/Akt-dependent mechanism.
AIMS: Toll-like receptor (TLR)-mediated signalling pathways have been implicated in myocardial ischaemia/reperfusion (I/R) injury. Activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway protects the myocardium from ischaemic injury. We hypothesized that the modulation of TLR2 would induce cardioprotection against I/R injury via activation of the PI3K/Akt signalling. METHODS AND RESULTS:Mice were treated with TLR2 ligands, peptidoglycan (PGN) or Pam3CSK4, respectively, 1 h before the hearts were subjected to ischaemia (1 h), followed by reperfusion (4 h). Infarct size was determined by triphenyltetrazolium chloride staining. Cardiac function and haemodynamic performance were evaluated. Infarct size was significantly reduced in PGN- or Pam3CSK4-treated mice compared with untreated I/R mice. Administration of TLR2 ligands improved cardiac function following I/R. PGN treatment increased the levels of phospho-Akt and phospho-GSK-3beta (glycogen synthase kinase-3beta), compared with untreated I/R hearts. PGN stimulation increased TLR2tyrosine phosphorylation and association of the p85 subunit of PI3K with TLR2. To investigate the role of PI3K/Akt signalling in PGN-induced cardioprotection, we administered the PI3K inhibitor, Wortmannin, to the mice 15 min before PGN treatment. We also administered PGN to kinase-deficient Akt (kdAkt) transgenic mice 1 h before myocardial I/R. Both PI3K inhibition and kdAkt mice abolished the cardioprotection induced by PGN. To examine the role of TLR2 in PGN-induced cardioprotection, we administrated PGN to TLR2 knockout mice 1 h before the hearts were subjected to I/R. PGN-induced cardioprotection was lost in TLR2-deficientmice. CONCLUSION: These results demonstrate that TLR2 ligands induced cardioprotection, which is mediated through a TLR2/PI3K/Akt-dependent mechanism.
Authors: Tetsuo Shioi; Julie R McMullen; Peter M Kang; Pamela S Douglas; Toshiyuki Obata; Thomas F Franke; Lewis C Cantley; Seigo Izumo Journal: Mol Cell Biol Date: 2002-04 Impact factor: 4.272
Authors: L Arbibe; J P Mira; N Teusch; L Kline; M Guha; N Mackman; P J Godowski; R J Ulevitch; U G Knaus Journal: Nat Immunol Date: 2000-12 Impact factor: 25.606
Authors: Jian-Wen Dong; Jesus G Vallejo; Huei-Ping Tzeng; James A Thomas; Douglas L Mann Journal: Am J Physiol Heart Circ Physiol Date: 2010-01-08 Impact factor: 4.733
Authors: Gordon D Brown; Jurgen Herre; David L Williams; Janet A Willment; Andrew S J Marshall; Siamon Gordon Journal: J Exp Med Date: 2003-04-28 Impact factor: 14.307
Authors: Honghui Yu; Tuanzhu Ha; Li Liu; Xiaohui Wang; Ming Gao; Jim Kelley; Race Kao; David Williams; Chuanfu Li Journal: Biochim Biophys Acta Date: 2012-05-14
Authors: Nicolás Eric Ponce; Roxana Carolina Cano; Eugenio Antonio Carrera-Silva; Ana Paula Lima; Susana Gea; Maria Pilar Aoki Journal: Med Microbiol Immunol Date: 2011-10-09 Impact factor: 3.402
Authors: Chen Lu; Li Liu; Yuling Chen; Tuanzhu Ha; Jim Kelley; John Schweitzer; John H Kalbfleisch; Race L Kao; David L Williams; Chuanfu Li Journal: J Immunol Date: 2011-06-27 Impact factor: 5.422